The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to current vector technology limiting efficacy, quality, and manufacturing viability. 

Lentitek has a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies and enable new applications such as in-vivo CAR-T and armoured CARs. Additionally, the improvement in manufacturing quality can lead to higher yields and improved product potency.